Anixa Biosciences…announced that the ﬁrst patient has been treated in the ﬁfth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer

liraltagene autoleucel (lira-cel) - Anixa Biosci, Moffitt Cancer Center

Jul 6, 2026